Lumen subsidiary refinances $2.4 billion term loan facility
Get Alerts LUMN Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 9.7%
Revenue Growth %: -11.3%
Join SI Premium – FREE
Lumen Technologies Inc. (NYSE: LUMN) announced that its subsidiary Level 3 Financing Inc. completed a refinancing of its term loan facility on May 13, 2026.
Level 3 refinanced all outstanding secured term B-4 loan facilities under its existing credit agreement and entered into a third amendment to reduce pricing on the term loan facility. The company had $2.4 billion of outstanding borrowings under the term loan facility following the transaction.
The term loan facility will accrue interest at Level 3's option of either the base rate plus an applicable margin or one-, three- or six-month SOFR plus an applicable margin. The applicable margin for SOFR loans will be 2.75% and for base rate loans will be 1.75%. The facility includes a SOFR floor of 0.00% and matures on March 27, 2032.
The amendment enables Bank of America N.A. to automatically succeed Wilmington Trust National Association as administrative agent within 180 days of the amendment date. Level 3 may voluntarily prepay loans without premium or penalty, except for a 1.00% premium on repricing transactions within six months of the amendment date.
The facility is guaranteed by substantially all of Level 3's material wholly-owned domestic subsidiaries and includes a separate unsecured parent guarantee from Lumen Technologies that the company may release at its discretion. The term loan is secured by a first priority lien on substantially all of Level 3's and the guarantors' current and fixed assets.
The facility contains standard negative covenants restricting Level 3's ability to merge, incur debt, grant liens, pay dividends, prepay junior debt, sell assets, or enter affiliate transactions, subject to permitted exceptions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- MacroGenics to receive $24.5M milestone from Sanofi on FDA approval
- Gil Issachar steps down as CTO at Firefly Neuroscience
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, BofA/Merrill Lynch, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share